Die interdisziplinäre Behandlung von Hautkrebs

Victoria Rudolph; Anna-Sophia Leven; Robin Eisenburger; Dirk Schadendorf; Susanne Wiegand

doi:10.1055/a-2171-4570

Laryngo-Rhino-Otologie, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Laryngorhinootologie 2024; 103(S 01): S100-S124
DOI: 10.1055/a-2171-4570

Referat

Interdisciplinary management of skin cancer

Artikel in mehreren Sprachen: deutsch | English

Victoria Rudolph^*

¹Klinik für Dermatologie, Universitätsmedizin Essen & Westdeutsches Tumorzentrum, Essen & Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort Essen/Düsseldorf & Nationales Centrum für Tumorerkrankungen (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, Universität Duisburg-Essen, Essen, Germany

,

Anna-Sophia Leven^*

¹Klinik für Dermatologie, Universitätsmedizin Essen & Westdeutsches Tumorzentrum, Essen & Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort Essen/Düsseldorf & Nationales Centrum für Tumorerkrankungen (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, Universität Duisburg-Essen, Essen, Germany

,

Robin Eisenburger

¹Klinik für Dermatologie, Universitätsmedizin Essen & Westdeutsches Tumorzentrum, Essen & Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort Essen/Düsseldorf & Nationales Centrum für Tumorerkrankungen (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, Universität Duisburg-Essen, Essen, Germany

,

Dirk Schadendorf^#

¹Klinik für Dermatologie, Universitätsmedizin Essen & Westdeutsches Tumorzentrum, Essen & Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort Essen/Düsseldorf & Nationales Centrum für Tumorerkrankungen (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, Universität Duisburg-Essen, Essen, Germany

,

Susanne Wiegand^#

²Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Leipzig, Leipzig, Deutschland

› Institutsangaben

Abstract

The interdisciplinary treatment of skin cancer in the head and neck area requires close collaboration between different specialist disciplines. The most common non-melanoma skin cancer tumor entities are cutaneous squamous cell carcinoma and basal cell carcinoma as well as their precursor lesions. One of the less common tumors is Merkel cell carcinoma, which also occurs primarily in light-exposed areas and, in contrast to squamous and basal cell carcinoma, is more likely to metastasize. Due to the low tendency of basal cell carcinoma as well as cutaneous squamous cell carcinoma to metastasize, a cure can often be achieved by surgery. If the tumor growth exceeds certain levels it may require collaboration between dermatology and otorhinolaryngology. The primary goal of this interdisciplinary collaboration is to achieve a functional, cosmetically and aesthetically acceptable result in addition to adequate tumor treatment. Depending on the stage of the tumor and the clinical course, a case may be discussed in an interdisciplinary tumor board in order to determine a personalised, appropriate and adequate treatment concept for each patient, including prevention, therapy and follow-up.

Volltext

Referenzen

Literatur
1 Die Haut – Anatomie und Funktion | DKG. (o. D.) https://www.krebsgesellschaft.de/onko-internetportal/basis-informationen-krebs/krebsarten/hautkrebs/der-aufbau-der-haut.html
2 Braakhuis BJM, Tabor MP, Kummer JA. et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730
3 Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology 2012; 166: 1069-1080
4 Rubin AI, Chen EH, Ratner D. Basal-Cell Carcinoma. New England Journal of Medicine 2005; 353: 2262-2269
5 Peterson SC, Eberl M, Vagnozzi AN. et al. Basal Cell Carcinoma Preferentially Arises from Stem Cells within Hair Follicle and Mechanosensory Niches. Cell Stem Cell 2015; 16: 400-412
6 Brantsch KD, Meisner C, Schönfisch B. et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720
7 Heppt MV, Leiter U, Steeb T. et al. S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020; 18: 275-294
8 Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: S23-S24
9 Palaniappan V, Karthikeyan K. Bowen’s disease. Indian Dermatol Online J 2022; 13: 177
10 Becker JC, Beer AJ, DeTemple VK. et al. S2k-Leitlinie – Merkelzellkarzinom – Update 2022. J Dtsch Dermatol Ges 2023; 21: 305-317
11 Becker JC, Stang A, DeCaprio JA. et al. Merkel cell carcinoma. Nat Rev Dis Primers 2017; 3: 17077
12 Feng H, Shuda M, Chang Y. et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-1100
13 Schrama D, Peitsch WK, Zapatka M. et al. Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology 2011; 131: 1631-1638
14 DeWane ME, Kelsey A, Oliviero M. et al. Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma. J Am Acad Dermatol 2019; 81: 823-833
15 Kallini JR, Jain SK, Khachemoune A. Lentigo Maligna: Review of Salient Characteristics and Management. Am J Clin Dermatol 2013; 14: 473-480
16 De Luca EV, Perino F, Di Stefani A. et al. Lentigo maligna: diagnosis and treatment. Giornale Italiano di Dermatologia e Venereologia 2020; 155
17 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, 2020, AWMF Registernummer: 032/024OL, http://www.leitlinienprogramm[1]onkologie.de/leitlinien/melanom/(abgerufen am: 30.08.2023).
18 Helbig D, Ziemer M, Dippel E. et al. S1-Leitlinie Atypisches Fibroxanthom (AFX) und pleomorphes dermales Sarkom (PDS). JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2022; 20: 235-245
19 Persa OD, Loquai C, Wobser M. et al. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas. Journal of the European Academy of Dermatology and Venereology 2019; 33: 1577-1580
20 Krebs in Deutschland für 2013/2014. 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2017
21 Asgari MM, Moffet HH, Ray GT. et al. Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012. JAMA Dermatol 2015; 151: 976
22 Schäfer I, Reusch M, Siebert J. et al. Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2014; 12: 803-811
23 Lang BM, Balermpas P, Bauer A. et al. S2k-Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Prävention und Nachsorge. J Dtsch Dermatol Ges 2019; 17: 214-231
24 Ling G, Ahmadian A, Persson Å. et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 2001; 20: 7770-7778
25 Kricker A, Armstrong BK, English DR. et al. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer 1995; 60: 489-494
26 Kricker A, Weber M, Sitas F. et al. Early Life UV and Risk of Basal and Squamous Cell Carcinoma in New South Wales, Australia. Photochem Photobiol 2017; 93: 1483-1491
27 Rosso S, Zanetti R, Martinez C. et al. The multicentre south European study „Helios“. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-1454
28 Wehner MR, Shive ML, Chren M-M. et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345: e5909-e5909
29 Penn I. Cancers in Renal Transplant Recipients. Adv Ren Replace Ther 2000; 7: 147-156
30 Gambini D, Passoni E, Nazzaro G. et al. Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response. Front Med (Lausanne) 2022; 9: 893063
31 Togsverd-Bo K, Lei U, Erlendsson AM. et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients – a randomized controlled trial. British Journal of Dermatology 2015; 172: 467-474
32 Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007; 127: 2323-2327
33 Euvrard S, Kanitakis J, Claudy A. Skin Cancers after Organ Transplantation. New England Journal of Medicine 2003; 348: 1681-1691
34 Ulrich C, Schmook T, Nindl I. et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. British Journal of Dermatology 2003; 149: 40-42
35 https://www.krebsinformationsdienst.de/aktuelles/2023/weisser-hautkrebs-berufskrankheit.php.
36 Lichter MD. Therapeutic Ionizing Radiation and the Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma. Arch Dermatol 2000; 136: 1007
37 Sugita K, Yamamoto O, Suenaga Y. Seven Cases of Radiation-Induced Cutaneous Squamous Cell Carcinoma. J UOEH 2000; 22: 259-267
38 Leiter U, Heppt MV, Steeb T. et al. S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020; 18: 400-413
39 Stang A, Becker JC, Nghiem P. et al. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment. Eur J Cancer 2018; 94: 47-60
40 Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33: 923-936
41 Fröhlich SM, Cazzaniga S, Kaufmann LS. et al. A Retrospective Cohort Study on Patients with Lentigo Maligna Melanoma. Dermatology 2019; 235: 340-345
42 Connolly KL, Nehal KS, Busam KJ. Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management. Melanoma Manag 2015; 2: 171-178
43 Whiteman DC, Watt P, Purdie DM. et al. Melanocytic Nevi, Solar Keratoses, and Divergent Pathways to Cutaneous Melanoma. JNCI Journal of the National Cancer Institute 2003; 95: 806-812
44 Howard GR, Nerad JA, Carter KD. et al. Clinical Characteristics Associated With Orbital Invasion of Cutaneous Basal Cell and Squamous Cell Tumors of the Eyelid. Am J Ophthalmol 1992; 113: 123-133
45 Leibovitch I, Mcnab A, Sullivan T. Et Al. Orbital Invasion by Periocular Basal Cell Carcinoma. Ophthalmology 2005; 112: 717-723
46 Niazi ZBM, Lamberty BGH. Perineural infiltration in basal cell carcinomas. Br J Plast Surg 1993; 46: 156-157
47 Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol 1983; 119: 373-377
48 Sun L, Chin R-I, Gastman B. et al. Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. JAMA Dermatol 2019; 155: 442
49 Eigentler TK, Leiter U, Häfner H-M. et al. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. Journal of Investigative Dermatology 2017; 137: 2309-2315
50 Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953; 6: 963-968
51 Braakhuis BJM, Tabor MP, Kummer JA. et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730
52 Braakhuis BJM, Tabor MP, Kummer JA. et al. A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730
53 Andruska N, Mahapatra L, Brenneman RJ. et al. Reduced Wide Local Excision Margins are Associated with Increased Risk of Relapse and Death from Merkel Cell Carcinoma. Ann Surg Oncol 2021; 28: 3312-3319
54 Song Y, Azari FS, Tang R. et al. Patterns of Metastasis in Merkel Cell Carcinoma. Ann Surg Oncol 2021; 28: 519-529
55 Farley CR, Perez MC, Soelling SJ. et al. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival. Ann Surg Oncol 2020; 27: 1978-1985
56 Schadendorf D, Lebbé C, zur Hausen A. et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71: 53-69
57 Harms KL, Healy MA, Nghiem P. et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 2016; 23: 3564-3571
58 Requena C, Manrique E, Nagore E. El lentigo maligno: actualización y claves en el diagnóstico y el tratamiento. Actas Dermosifiliogr 2023; 114: 413-424
59 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prävention von Hautkrebs, Langversion 2.1, 2021, AWMF Registernummer: 032/052OL, https://www.leitlinienprogramm[1]onkologie.de/leitlinien/hautkrebs-praevention/(abgerufen am: 29.07.2023)).
60 Grob JJ, Gaudy-Marqueste C, Guminski A. et al. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology 2021; 35: 2149-2153
61 Christensen E, Mjønes P, Grimstad Ø. et al. Diagnostic Accuracy in Subtyping Basal Cell Carcinoma by Clinical Diagnosis Compared with Punch Biopsy. Acta Dermato Venereologica 2014; 0
62 Roozeboom M, Kreukels H, Nelemans P. et al. Subtyping Basal Cell Carcinoma by Clinical Diagnosis Versus Punch Biopsy. Acta Dermato Venereologica 2015; 95: 996-998
63 Armstrong LTD, Magnusson MR, Guppy MPB. Risk factors for recurrence of facial basal cell carcinoma after surgical excision: A follow-up analysis. Journal of Plastic, Reconstructive & Aesthetic Surgery 2017; 70: 1738-1745
64 Humphreys TR, Shah K, Wysong A. et al. The role of imaging in the management of patients with nonmelanoma skin cancer. J Am Acad Dermatol 2017; 76: 591-607
65 Schmitz L, Kahl P, Majores M. et al. Actinic keratosis: correlation between clinical and histological classification systems. Journal of the European Academy of Dermatology and Venereology 2016; 30: 1303-1307
66 Wheller L, Soyer HP. Clinical Features of Actinic Keratoses and Early Squamous Cell Carcinoma 2015; 58-63
67 Akay BN, Kocyigit P, Heper AO. et al. Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. British Journal of Dermatology 2010; 163: 1212-1217
68 Huerta-Brogeras M, Olmos O, Borbujo J. et al. Validation of Dermoscopy as a Real-time Noninvasive Diagnostic Imaging Technique for Actinic Keratosis. Arch Dermatol 2012; 148: 1159
69 Schmitz L, Gupta G, Stücker M. et al. Evaluation of two histological classifications for actinic keratoses –<scp>PRO</scp>classification scored highest inter-rater reliability. Journal of the European Academy of Dermatology and Venereology 2019; 33: 1092-1097
70 Fernández-Figueras MT, Carrato C, Sáenz X. et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. Journal of the European Academy of Dermatology and Venereology 2015; 29: 991-997
71 Stratigos A, Garbe C, Lebbe C. et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989-2007
72 de Bree R, Takes RP, Castelijns JA. et al. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. Head Neck 2015; 37: 1829-1839
73 Liao L-J, Lo W-C, Hsu W-L. et al. Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck—a meta-analysis comparing different imaging modalities. BMC Cancer 2012; 12: 236
74 Walsh NM, Cerroni L. Merkel cell carcinoma: A review. J Cutan Pathol 2021; 48: 411-421
75 Singh N, Alexander NA, Lachance K. et al. Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. J Am Acad Dermatol 2021; 84: 330-339
76 Jenkins LN, Howle JR, Veness MJ. Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: the Westmead Hospital experience. ANZ J Surg 2019; 89: 520-523
77 Swetter SM, Tsao H, Bichakjian CK. et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019; 80: 208-250
78 Geisse J, Caro I, Lindholm J. et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733
79 Roozeboom MH, Arits AHMM, Mosterd K. et al. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. Journal of Investigative Dermatology 2016; 136: 1568-1574
80 Arits AH, Mosterd K, Essers BA. et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-654
81 Peng Q, Warloe T, Berg K. et al. 5-Aminolevulinic acid-based photodynamic therapy. Cancer 1997; 79: 2282-2308
82 Basset-Seguin N, Ibbotson SH, Emtestam L. et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-553
83 Szeimies R, Ibbotson S, Murrell D. et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology 2008; 22: 1302-1311
84 Kuflik EG. Cryosurgery for Skin Cancer: 30-Year Experience and Cure Rates. Dermatologic Surgery 2004; 30: 297-300
85 Har-Shai Y, Sommer A, Gil T. et al. Intralesional cryosurgery for the treatment of basal cell carcinoma of the lower extremities in elderly subjects: a feasibility study. Int J Dermatol 2016; 55: 342-350
86 Berking C, Hauschild A, Kölbl O. et al. Basal cell carcinoma. -treatments for the commonest skin cancer. Dtsch Arztebl Int 2014; 111: 389-395
87 Drucker AM, Adam GP, Rofeberg V. et al. Treatments of Primary Basal Cell Carcinoma of the Skin. Ann Intern Med 2018; 169: 456-466
88 McKeown SR, Hatfield P, Prestwich RJ. et al. Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol 2015; 88: 20150405
89 Dirschka T, Gupta G, Micali G. et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. Journal of Dermatological Treatment 2017; 28: 431-442
90 Arcuri D, Ramchatesingh B, Lagacé F. et al. Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review. Int J Mol Sci 2023; 24: 4989
91 Smolinski MP, Bu Y, Clements J. et al. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). J Med Chem 2018; 61: 4704-4719
92 Blauvelt A, Kempers S, Lain E. et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. New England Journal of Medicine 2021; 384: 512-520
93 Mendenhall WM, Amdur RJ, Hinerman RW. et al. Skin Cancer of the Head and Neck With Perineural Invasion. Am J Clin Oncol 2007; 30: 93-96
94 Lansbury L, Bath-Hextall F, Perkins W. et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013; 347: f6153-f6153
95 Fang LC, Lemos B, Douglas J. et al. Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. Cancer 2010; 116: 1783-1790
96 Farshad A, Burg G, Panizzon R. et al. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. British Journal of Dermatology 2002; 146: 1042-1046
97 Trakatelli M, Morton C, Nagore E. et al. Update of the European guidelines for basal cell carcinoma management. European Journal of Dermatology 2014; 24: 312-329
98 Kauvar ANB, Cronin T, Roenigk R. et al. Consensus for Nonmelanoma Skin Cancer Treatment. Dermatologic Surgery 2015; 41: 550-571
99 Gulleth Y, Goldberg N, Silverman RP. et al. What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature. Plast Reconstr Surg 2010; 126: 1222-1231
100 Nahhas AF, Scarbrough CA, Trotter S. A Review of the Global Guidelines on Surgical Margins for Nonmelanoma Skin Cancers. J Clin Aesthet Dermatol 2017; 10: 37-46
101 Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123: 340-344
102 Bichakjian CK, Olencki T, Aasi SZ. et al. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2016; 14: 574-597
103 Möhrle M. Von der „mikroskopisch kontrollierten Chirurgie” zur „3D-Histologie” – eine Erfolgsgeschichte. Aktuelle Derm 2009; 35: 283-286
104 Chen OM, Kim K, Steele C. et al. Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. Cancers (Basel) 2022; 14: 3720
105 Rowe De, Carroll Rj, Day Cl. Mohs Surgery Is the Treatment of Choice for Recurrent (Previously Treated) Basal Cell Carcinoma. J Dermatol Surg Oncol 1989; 15: 424-431
106 Abramson AK, Krasny MJ, Goldman GD. Tangential Shave Removal of Basal Cell Carcinoma. Dermatologic Surgery 2013; 39: 387-392
107 Stratigos AJ, Garbe C, Dessinioti C. et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer 2020; 128: 60-82
108 Zhang J, Wang Y, Wijaya WA. et al. Efficacy and prognostic factors of adjuvant radiotherapy for cutaneous squamous cell carcinoma: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology 2021; 35: 1777-1787
109 Sahovaler A, Krishnan RJ, Yeh DH. et al. Outcomes of Cutaneous Squamous Cell Carcinoma in the Head and Neck Region With Regional Lymph Node Metastasis. JAMA Otolaryngology–Head & Neck Surgery 2019; 145: 352
110 Porceddu SV, Bressel M, Poulsen MG. et al. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. Journal of Clinical Oncology 2018; 36: 1275-1283
111 Han AY, Patel PB, Anderson M. et al. Adjuvant radiation therapy improves patient survival in early-stage merkel cell carcinoma: A 15-year single-institution study. Laryngoscope 2018; 128 1862-1866
112 Hazan C, Dusza SW, Delgado R. et al. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58: 142-148
113 Iznardo H, Garcia-Melendo C, Yélamos O. <p>Lentigo Maligna: Clinical Presentation and Appropriate Management</p>. . Clin Cosmet Investig Dermatol 2020; Volume 13: 837-855
114 Robinson JK. Actinic Cheilitis: A Prospective Study Comparing Four Treatment Methods. Archives of Otolaryngology – Head and Neck Surgery 1989; 115: 848-852
115 Lai M, Pampena R, Cornacchia L. et al. Treatments of actinic cheilitis: A systematic review of the literature. J Am Acad Dermatol 2020; 83: 876-887
116 Perea-Milla López E, Miñarro-del Moral RM, Martínez-García C. et al. Lifestyles, environmental and phenotypic factors associated with lip cancer: a case–control study in southern Spain. Br J Cancer 2003; 88: 1702-1707
117 Wang DM, Kraft S, Rohani P. et al. Association of Nodal Metastasis and Mortality With Vermilion vs Cutaneous Lip Location in Cutaneous Squamous Cell Carcinoma of the Lip. JAMA Dermatol 2018; 154: 701
118 Gooris PJJ, Vermey A, de Visscher JGAM. et al. Supraomohyoid neck dissection in the management of cervical lymph node metastases of squamous cell carcinoma of the lower lip. Head Neck 2002; 24: 678-683
119 Bhandari K, Wang D, Li S. et al. Primary cN0 lip squamous cell carcinoma and elective neck dissection: Systematic review and meta-analysis. Head Neck 2015; 37: 1392-1400
120 Newlands C, Currie R, Memon A. et al. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130: S125-S132
121 Martinez J-C, Jl Cook. High-Risk Cutaneous Squamous Cell Carcinoma without Palpable Lymphadenopathy: Is There a Therapeutic Role for Elective Neck Dissection?. Dermatologic Surgery 2007; 33: 410-420
122 Amit M, Liu C, Mansour J. et al. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 2021; 127: 4413-4420
123 Peiffer N, Kutz JW, Myers LL. et al. Patterns of Regional Metastasis in Advanced Stage Cutaneous Squamous Cell Carcinoma of the Auricle. Otolaryngology–Head and Neck Surgery 2011; 144: 36-42
124 Ferlito A, Rinaldo A, Silver CE. et al. Elective and therapeutic selective neck dissection. Oral Oncol 2006; 42: 13-24
125 Audet N, Palme CE, Gullane PJ. et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 2004; 26: 727-732
126 Rotman A, Kerr SJ, Giddings CEB. Elective neck dissection in metastatic cutaneous squamous cell carcinoma to the parotid gland: A systematic review and meta-analysis. Head Neck 2019; 41: 1131-1139
127 Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion?. Cancer 2007; 109: 1053-1059
128 Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: a 15-year institutional experience and statistical analysis of 721 reported cases. British Journal of Dermatology 2016; 174: 273-281
129 Stokes JB, Graw KS, Dengel LT. et al. Patients With Merkel Cell Carcinoma Tumors≤1.0 cm in Diameter Are Unlikely to Harbor Regional Lymph Node Metastasis. Journal of Clinical Oncology 2009; 27: 3772-3777
130 Iyer JG, Storer BE, Paulson KG. et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 2014; 70: 637-643
131 Timmer FCA, Klop WMC, Relyveld GN. et al. Merkel cell carcinoma of the head and neck: emphasizing the risk of undertreatment. European Archives of Oto-Rhino-Laryngology 2016; 273: 1243-1251
132 Cheraghlou S, Agogo GO, Girardi M. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatol 2019; 155: 803-811
133 Hong NJL, Wright FC, Gagliardi AR. et al. Examining the potential relationship between multidisciplinary cancer care and patient survival: An international literature review. J Surg Oncol 2010; 102: 125-134
134 Lamb BW, Brown KF, Nagpal K. et al. Quality of Care Management Decisions by Multidisciplinary Cancer Teams: A Systematic Review. Ann Surg Oncol 2011; 18: 2116-2125
135 Bundesministerium für Gesundheit. Broschüre: Nationaler Krebsplan – Handlungsfelder, Ziele und Umsetzungsempfehlungen. Berlin. 2012
136 Ascierto PA, Schadendorf D. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. J Immunother Cancer 2022; 10: e005082
137 Harrington C, Kwan W. Radiotherapy and Conservative Surgery in the Locoregional Management of Merkel Cell Carcinoma: The British Columbia Cancer Agency Experience. Ann Surg Oncol 2016; 23: 573-578
138 Takagishi SR, Marx TE, Lewis C. et al. Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck. Adv Radiat Oncol 2016; 1: 244-251
139 Becker JC, Ugurel S, Leiter U. et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. The Lancet 2023;
140 Ferrarotto R, Nagarajan P, Maronge JM. et al. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology–Head & Neck Surgery 2023;
141 Gross ND, Miller DM, Khushalani NI. et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine 2022; 387: 1557-1568
142 Topalian SL, Bhatia S, Amin A. et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. Journal of Clinical Oncology 2020; 38: 2476-2487
143 Sekulic A, Migden MR, Oro AE. et al. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine 2012; 366: 2171-2179
144 Migden MR, Guminski A, Gutzmer R. et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716-728
145 Lear JT, Migden MR, Lewis KD. et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venereology 2018; 32: 372-381
146 Stratigos AJ, Sekulic A, Peris K. et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 848-857
147 Stratigos AJ, Sekulic A, Peris K. et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 848-857
148 Rischin D, Khushalani NI, Schmults CD. et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021; 9: e002757
149 Hughes BGM, Munoz-Couselo E, Mortier L. et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021; 32: 1276-1285
150 Hitt R, Irigoyen A, Cortes-Funes H. et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Annals of Oncology 2012; 23: 1016-1022
151 Glutsch V, Kneitz H, Gesierich A. et al. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. Cancer Immunology, Immunotherapy 2021; 70: 2087-2093
152 Nghiem P, Kaufman HL, Bharmal M. et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncology 2017; 13: 1263-1279